Anaheim Bio Launches With Funding for Crystal Disease Drug

Company Anaheim Bio Event Type Launch and Series A financing (€40 million) Modality Small molecule (oral) Asset ANA-1 Target Extracellular pyrophosphate (PPi) Disease Area Calcium pyrophosphate deposition disease Summary Anaheim Bio launched on November 5 with an oversubscribed €40 million Series A to advance ANA-1,…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Agenus Raises Up to $340M on Neoadjuvant MSS Colon Cancer
Infinimmune Raises $75 Million for Two Atopic-Dermatitis Antibodies
GenScript Raises HK$2.33 Billion for AIDD Expansion
TriGemX Raises $94 Million for Phase 3 Migraine Trials